### FWO DMP Template - Flemish Standard Data Management Plan

#### **Version KU Leuven**

Project supervisors (from application round 2018 onwards) and fellows (from application round 2020 onwards) will, upon being awarded their project or fellowship, be invited to develop their answers to the data management related questions into a DMP. The FWO expects a **completed DMP no later than 6 months after the official start date** of the project or fellowship. The DMP should not be submitted to FWO but to the research co-ordination office of the host institute; FWO may request the DMP in a random check.

At the end of the project, the **final version of the DMP** has to be added to the final report of the project; this should be submitted to FWO by the supervisor-spokesperson through FWO's e-portal. This DMP may of course have been updated since its first version. The DMP is an element in the final evaluation of the project by the relevant expert panel. Both the DMP submitted within the first 6 months after the start date and the final DMP may use this template.

The DMP template used by the Research Foundation Flanders (FWO) corresponds with the Flemish Standard Data Management Plan. This Flemish Standard DMP was developed by the Flemish Research Data Network (FRDN) Task Force DMP which comprises representatives of all Flemish funders and research institutions. This is a standardized DMP template based on the previous FWO template that contains the core requirements for data management planning. To increase understanding and facilitate completion of the DMP, a standardized **glossary** of definitions and abbreviations is available via the following link.

	1. General Project Information
Name Grant Holder & ORCID	Pieter Gillard, ORCID: 0000-0001-9111-4561
Contributor name(s) (+ ORCID) & roles	Margaretha Visser (0000-0003-0216-4028) – PhD; sub-investigator; UZ/KU Leuven; data collection and data analysis
	Sara Charleer (0000-0003-2100-4927) – PhD; post-Doc UZ/KU Leuven: data collection and data analysis Laura Valgaerts, ORCID: 0009-0002-2501-6554, PhD UZ/KU Leuven: data collection and data analysis
Project number <sup>1</sup> & title	Assessing novel technologies and glucometrics to improve glucose control and quality of life of people with type 1 diabetes
Funder(s) GrantID <sup>2</sup>	
Affiliation(s)	KU Leuven
	☐ Universiteit Antwerpen
	☐ Universiteit Gent
	☐ Universiteit Hasselt
	□ Vrije Universiteit Brussel
	□ Other:
	ROR identifier KU Leuven: 05f950310

<sup>&</sup>lt;sup>1</sup> "Project number" refers to the institutional project number. This question is optional. Applicants can only provide one project number.

<sup>&</sup>lt;sup>2</sup> Funder(s) GrantID refers to the number of the DMP at the funder(s), here one can specify multiple GrantIDs if multiple funding sources were used.

Please provide a sho	rt project description
----------------------	------------------------

Type 1 diabetes (T1D) is caused by the destruction of the cells that make insulin. People with T1D need to check blood glucose several times a day and administer the appropriate amount of insulin. Incorrect insulin dosing can lead to very low or chronically high glucose levels which can cause coma or organ damage. Novel technologies such as continuous glucose monitoring (CGM) and hybrid closed loop (HCL) systems offer the opportunity of improved treatment, but better knowledge regarding possible benefits and utility of different devices is needed. I will investigate the impact of different systems on glucose control and quality of life (QOL) of people with T1D and whether using data generated by these CGM systems (glucometrics) can help improving diabetes care. First, I will study long-term beneficial effects of real-time (rt) CGM and its health-economic impact in a pre-specified analysis of the ALERTT1 trial. Second, I will investigate if switching to more advanced systems or insulins impacts glucometrics and QOL. Third, I will collaborate with a group of machine learning experts to develop an artificial intelligence based model using data of patients on rtCGM systems and physical activity trackers. We will assess if this model can help to calculate how much insulin to inject around physical activity. Last, I will study the exact relation between number of insulin producing cells and glucometrics in patients who were autotransplanted with those cells after pancreatectomy.

#### 2. Research Data Summary

List and describe all datasets or research materials that you plan to generate/collect or reuse during your research project. For each dataset or data type (observational, experimental etc.), provide a short name & description (sufficient for yourself to know what data it is about), indicate whether the data are newly generated/collected or reused, digital or physical, also indicate the type of the data (the kind of content), its technical format (file extension), and an estimate of the upper limit of the volume of the data <sup>3</sup>.

				ONLY FOR DIGITAL DATA	ONLY FOR DIGITAL DATA	ONLY FOR DIGITAL DATA	ONLY FOR PHYSICAL DATA
Dataset	Description	New or Reused	Digital or	Digital Data Type	Digital Data	Digital Data	Physical Volume
Name			Physical		Format	Volume (MB, GB,	
						TB)	
INRANGE –	Data (clinical	□ Generate new	□ Digital	☐ Audiovisual	SPSS Statistics	⊠ < 1 GB	
Medtronic	data, glucose	data	☐ Physical	☐ Images	Data Document	□ < 100 GB	
780G	data and	☐ Reuse existing		☐ Sound	(.sav)	□ < 1 TB	
database	questionnaires)	data		⊠ Numerical		□ < 5 TB	
	, digitalized in			☐ Textual		□ > 5 TB	
	SPSS database			☐ Model		□NA	
				☐ Software			
				☐ Other:			
INRANGE –	Data (clinical	□ Generate new	□ Digital	☐ Audiovisual	SPSS Statistics	⊠ < 1 GB	
Tandem	data, glucose	data	☐ Physical	☐ Images	Data Document	□ < 100 GB	
database	data and	☐ Reuse existing		☐ Sound	(.sav)	□ < 1 TB	
	questionnaires)	data		⊠ Numerical		□ < 5 TB	
	collected via			☐ Textual		□ > 5 TB	
	eCRF Castor and			☐ Model		□NA	
	digitalized in			☐ Software			
	SPSS database			☐ Other:			
GLADE –	Data (clinical,	□ Generate new	□ Digital	☐ Audiovisual	SPSS Statistics	⊠ < 1 GB	
University	glucose, and	data	☐ Physical	☐ Images	Data Document	□ < 100 GB	
Hospitals	questionnaires)	☐ Reuse existing		☐ Sound	(.sav)	□ < 1 TB	
Leuven	collected via	data				□ < 5 TB	

<sup>&</sup>lt;sup>3</sup> Add rows for each dataset you want to describe.

database	CSV format			☐ Textual		□ > 5 TB	
	from			☐ Model		□NA	
	proprietary			☐ Software			
	software			☐ Other:			
	platforms, and						
	digitalized in						
	SPSS database						
	digitalized in						
	SPSS database						
ALERTT1 - (6-	Data (clinical	⊠ Generate new	□ Digital	☐ Audiovisual	SPSS Statistics	⊠ < 1 GB	Multiple folders
month RCT +	data, glucose	data	□ Physical	☐ Images	Data Document	□ < 100 GB	with original study
30-month	data and	☐ Reuse existing		☐ Sound	(.sav)	□ < 1 TB	documents (paper),
extension)	questionnaires)	data				□ < 5 TB	stored centrally (UZ
database	collected via			☐ Textual		□ > 5 TB	Leuven) and on-site
	OpenClinica and			☐ Model		□NA	
	digitalized in			☐ Software			
	SPSS database			☐ Other:			
ENHANCED1 -	Data (physical	⊠ Generate new	□ Digital	☐ Audiovisual	PostGresDB,	□ < 1 GB	
database	activity data,	data	☐ Physical	☐ Images	MongoDB, and	⊠ < 100 GB	
	food intake	☐ Reuse existing		☐ Sound	MinIO	□ < 1 TB	
	data, glucose	data				□ < 5 TB	
	and insulin data)			☐ Textual		□ > 5 TB	
	collected via			☐ Model		□ NA	
	application			☐ Software			
	programming			☐ Other:			
	interfaces and						
	digitalized in						
	different						
	databases						

ATHLETE1-	Data collected	☐ Generate new	□ Digital	☐ Audiovisual	PostGresDB,	□ < 1 GB
database	in ENHANCED1	data	☐ Physical	☐ Images	MongoDB, and	⊠ < 100 GB
	study	□ Reuse existing		☐ Sound	MinIO	□ < 1 TB
		data		⊠ Numerical		□ < 5 TB
				☐ Textual		□ > 5 TB
				☐ Model		□NA
				☐ Software		
				☐ Other:		
Transplant-	All data	☐ Generate new	□ Digital	☐ Audiovisual	Database (.sav)	⊠ < 1 GB
database	combined of	data	☐ Physical	☐ Images		□ < 100 GB
	each study	□ Reuse existing		☐ Sound		□ < 1 TB
	(RESCUE,	data		⊠ Numerical		□ < 5 TB
	FUTURE,			☐ Textual		□ > 5 TB
	ALERTT1,			☐ Model		□NA
	INRANGE)			☐ Software		
				☐ Other:		
GUIDANCE:						

The data description forms the basis of your entire DMP, so make sure it is detailed and complete. It includes digital and physical data and encompasses the whole spectrum ranging from raw data to processed and analysed data including analysis scripts and code. Physical data are all materials that need proper management because they are valuable, difficult to replace and/or ethical issues are associated. Materials that are not considered data in an RDM context include your own manuscripts, theses and presentations; documentation is an integral part of your datasets and should described under documentation/metadata.

RDM Guidance on data

If you reuse existing data, please specify the FOR ATHLETE1-database: Data collected in the ENHANCED1 (NCT05670366) will be reused. source, preferably by using a persistent identifier (e.g. DOI, Handle, URL etc.) per FOR Transplant database, data of the following studies will be reused: dataset or data type. **FUTURF:** NCT02898714 DOI: 10.2337/dc19-1610 (results until 12 months) DOI: 10.1089/dia.2022.0452 (results until 24 months) **RESCUE:** NCT02601729 - DOI: 10.1210/jc.2017-02498 (results until 12 months) DOI: 10.2337/dc20-1531 (results until 24 months) **INRANGE:** NCT04414280 ALFRTT1: NCT03772600 DOI: 10.1016/S0140-6736(21)00789-3 (results until 6 months) - DOI: 10.1016/S2213-8587(22)00352-7 (extension phase: results until 24 months) Are there any ethical issues concerning the ☑ Yes, human subject data; provide SMEC or EC approval number: INRANGE Medtronic and Tandem: creation and/or use of the data B322201942115; ALERTT1 B322201838252; ENHANCED-1: B3222022000933; RESCUE: B322201526850; (e.g. experiments on humans or animals, dual FUTURE: B322201526850 use)? If so, refer to specific datasets or data ☐ Yes, animal data; provide ECD reference number: types when appropriate and provide the ☐ Yes, dual use; provide approval number: relevant ethical approval number. ☐ No Additional information: For retrospective studie no specific EC approval (B-number) is provided. All studies on human data are or will be submitted for ethical approval (see S-number below for all S-numbers)

Will you process personal data <sup>4</sup> ? If so, please refer to specific datasets or data types when	☑ Yes (provide PRET G-number or EC S-number below). INRANGE Medtronic and Tandem: S63351;  ALERTT1 S61830; ENHANCED-1: S64550; RESCUE: S58626; FUTURE: S59342; ATHLETE-1 S66569; GLADE:
appropriate and provide the KU Leuven or UZ	S66239; TRANSPLANT:S68425;
Leuven privacy register number (G or S number).	□ No
	Additional information:
Does your work have potential for commercial	☐ Yes
valorization (e.g. tech transfer, for example spin-	⊠ No
offs, commercial exploitation,)?	If yes, please comment:
If so, please comment per dataset or data type	
where appropriate.	
Do existing 3rd party agreements restrict	☐ Yes
exploitation or dissemination of the data you	⊠ No
(re)use (e.g. Material/Data transfer agreements,	If yes, please explain:
research collaboration agreements)?	
If so, please explain to what data they relate and	
what restrictions are in place.	
Are there any other legal issues, such as	⊠ Yes
intellectual property rights and ownership, to be	□ No
managed related to the data you (re)use?	If yes, please explain:
If so, please explain to what data they relate and	FOR ALERTT1 there is a contract agreement that pseudonymized data will be transferred to Dexcom
which restrictions will be asserted.	FOR TRANSPLANT there will be a contract agreement on the transfer of pseudonymized data to VERTEX

## 3. Documentation and Metadata

<sup>&</sup>lt;sup>4</sup> See Glossary Flemish Standard Data Management Plan

Clearly describe what approach will be followed to capture the accompanying information necessary to keep data understandable and usable, for yourself and others, now and in the future (e.g. in terms of documentation levels and types required, procedures used, Electronic Lab Notebooks, README.txt files, Codebook.tsv etc. where this information is recorded).  RDM guidance on documentation and metadata.	SPSS Statistics Data Documents (.sav) contain a description (i.e. variable list, measurement units, scale information) of each variable in order to keep the data understandable and usable.  Readme.txt files provide the necessary information to keep the data in database understandable and usable.
Will a metadata standard be used to make it easier to find and reuse the data?	☐ Yes ⊠ No
casici to find and rease the data:	If yes, please specify (where appropriate per dataset or data type) which metadata standard will be used:
If so, please specify which metadata standard will be used. If not, please specify which metadata will be created to make the data easier to find and reuse.	If no, please specify (where appropriate per dataset or data type) which metadata will be created: There is no metadata standard in our field. Project metadata of all databases (.sav) were created manually.
REPOSITORIES COULD ASK TO DELIVER METADATA IN A CERTAIN FORMAT, WITH SPECIFIED ONTOLOGIES AND VOCABULARIES, I.E. STANDARD LISTS WITH UNIQUE IDENTIFIERS.	

# 4. Data Storage & Back-up during the Research Project

Where will the data be stored?	Shared network drive (J-drive)
	☐ Personal network drive (I-drive)
Consult the interactive KU Leuven storage guide to	☐ OneDrive (KU Leuven)
find the most suitable storage solution for your data.	☐ Sharepoint online
	☐ Sharepoint on-premis
	☐ Large Volume Storage
	☐ Digital Vault
	☑ Other: All the physical data (informed consent forms, collected data on paper) with personal data of
	the participants are stored in a safe location in UZLeuven, only accessible by the research team.
How will the data be backed up?	☑ Standard back-up provided by KU Leuven/UZ Leuven ICTS for my storage solution
•	☐ Personal back-ups I make (specify)
WHAT STORAGE AND BACKUP PROCEDURES WILL BE IN PLACE TO	☐ Other (specify)
PREVENT DATA LOSS?	
Is there currently sufficient storage & backup	⊠ Yes
capacity during the project? If yes, specify	□ No
concisely. If no or insufficient storage or backup	
capacities are available, then explain how this	If no, please specify:
will be taken care of.	
How will you ensure that the data are securely	Paper data is secured in a safe location where only members of the research team have access.
stored and not accessed or modified by	
unauthorized persons?	Data stored on the central servers are only accessible by those who have access to these digital folders. Only
	members of the research team have access.
CLEARLY DESCRIBE THE MEASURES (IN TERMS OF PHYSICAL SECURITY,	
NETWORK SECURITY, AND SECURITY OF COMPUTER SYSTEMS AND	
FILES) THAT WILL BE TAKEN TO ENSURE THAT STORED AND	
TRANSFERRED DATA ARE SAFE.  Guidance on security for research data	
	I .

·	osts linked to data storage and back-up, if any, will be covered by the research grant. o costs
---	---

	5. Data Preservation after the end of the Research Project
Which data will be retained for at least five years (or longer, in agreement with other retention policies that are applicable) after the end of the project? In case some data cannot be preserved, clearly state the reasons for this (e.g. legal or contractual restrictions, storage/budget issues, institutional policies).  Guidance on data preservation	<ul> <li>□ All data will be preserved for 10 years according to KU Leuven RDM policy</li> <li>☑ All data will be preserved for 25 years according to CTC recommendations for clinical trials with medicinal products for human use and for clinical experiments on humans</li> <li>□ Certain data cannot be kept for 10 years (explain)</li> </ul>
Where will these data be archived (stored and curated for the long-term)?  Dedicated data repositories are often the best place to preserve your data. Data not suitable for preservation in a repository can be stored using a KU Leuven storage solution, consult the interactive KU Leuven storage guide.	<ul> <li>□ KU Leuven RDR</li> <li>□ Large Volume Storage (longterm for large volumes)</li> <li>☑ Shared network drive (J-drive)</li> <li>□ Other (specifiy):</li> <li>Paper data will be sent to an archive (OASIS: https://www.oasisgroup.be/)</li> <li>Digital data (anonymized) will be stored on the central server of UZ Leuven.</li> </ul>

What are the expected costs for data	Data storage is estimated at €10.000.
preservation during the expected retention	Costs linked to data storage and back-up will be covered by the research grant.
period? How will these costs be covered?	

	6. Data Sharing and Reuse
Will the data (or part of the data) be made	☐ Yes, as open data
available for reuse after/during the project?	☐ Yes, as embargoed data (temporary restriction)
Please explain per dataset or data type which	☑ Yes, as restricted data (upon approval, or institutional access only)
data will be made available.	☐ No (closed access)
	☐ Other, please specify:
NOTE THAT 'AVAILABLE' DOES NOT NECESSARILY MEAN THAT THE	
DATA SET BECOMES OPENLY AVAILABLE, CONDITIONS FOR ACCESS	
AND USE MAY APPLY. AVAILABILITY IN THIS QUESTION THUS ENTAILS BOTH OPEN & RESTRICTED ACCESS. FOR MORE INFORMATION:	
HTTPS://WIKI.SURFNET.NL/DISPLAY/STANDARDS/INFO-EU-REPO/#INF	
OEUREPO-ACCESSRIGHTS	
If access is restricted, please specify who will be	Anonymous data are shared with centers participating the trials, based on research questions mentioned
able to access the data and under what	in an approved protocol by the relevant ethical committees. Selected anonymous data collected in the
conditions.	study and additional documents can be made available to others on the basis of a reasonable request and
	under a data transfer agreement signed by the institutions.

Are there any factors that restrict or prevent the sharing of (some of) the data (e.g. as defined in an agreement with a 3rd party, legal restrictions)? Please explain per dataset or data type where appropriate.	<ul> <li>✓ Yes, privacy aspects</li> <li>✓ Yes, intellectual property rights</li> <li>☐ Yes, ethical aspects</li> <li>☐ Yes, aspects of dual use</li> <li>☒ Yes, other</li> <li>☐ No</li> <li>If yes, please specify: for all databases, sharing of data should follow privacy regulation, legal restrictions and contracts will need to stipulate that intellectual property will remain at KULeuven/UZLeuven</li> </ul>
Where will the data be made available? If already known, please provide a repository per dataset or data type.	<ul> <li>□ KU Leuven RDR</li> <li>□ Other data repository (specify)</li> <li>☑ Other (specify). Data will be made available if an agreement (approved by EC and CTC) is made with outside parties. It will also specify which data repository will be used or how the data will be shared.</li> </ul>
When will the data be made available?	<ul> <li>☑ Upon publication of research results</li> <li>☐ Specific date (specify)</li> <li>☐ Other (specify)</li> </ul>

Which data usage licenses are you going to	☐ CC-BY 4.0 (data)		
provide? If none, please explain why.	☐ ☑ Data Transfer Agreement (restricted data)		
	☐ MIT licence (code)		
A DATA USAGE LICENSE INDICATES WHETHER THE DATA CAN BE REUSED OR NOT AND UNDER WHAT CONDITIONS. IF NO LICENCE IS GRANTED, THE DATA ARE IN A GREY ZONE AND CANNOT BE LEGALLY REUSED. DO NOTE THAT YOU MAY ONLY RELEASE DATA UNDER A LICENCE CHOSEN BY YOURSELF IF IT DOES NOT ALREADY FALL UNDER ANOTHER LICENCE THAT MIGHT PROHIBIT THAT.	☐ GNU GPL-3.0 (code) ☐ Other (specify) Data will be made available if an agreement (approved by EC and CTC) is made with outside parties. It will also specify which data repository will be used or how the data will be shared.		
Check the <u>RDR guidance on licences</u> for data and			
software sources code or consult the <u>License selector</u>			
<u>tool</u> to help you choose.			
Do you intend to add a PID/DOI/accession number to your dataset(s)? If already available, please provide it here.  INDICATE WHETHER YOU INTEND TO ADD A PERSISTENT AND UNIQUE IDENTIFIER IN ORDER TO IDENTIFY AND RETRIEVE THE DATA.	<ul> <li>✓ Yes, a PID will be added upon deposit in a data repository</li> <li>☐ My dataset already has a PID</li> <li>☐ No</li> </ul>		
What are the expected costs for data sharing? How will these costs be covered?			
	7 Posponsibilities		

# The PhD researchers (Jolien De Meulemeester, Laura Valgaerts, future others) or sub-investigator (Margaretha Visser) will be responsible for managing data documentation and metadata, together with the team of research assistants (Head Hilde Morobe). Ultimately, managing data documentation and metadata is the responsibility of the supervisor (Pieter Gillard).

Who will manage data storage and backup	The PhD researchers (Jolien De Meulemeester, Laura Valgaerts, future others) or sub-investigator
during the research project?	(Margaretha Visser) will manage data storage and backup during the PhD research, together with the
	team of research assistants (Head Hilde Morobe). Ultimately, managing data storage and backup is the
	responsibility of the supervisor (Pieter Gillard).
Who will manage data preservation and	The PhD researchers (Jolien De Meulemeester, Laura Valgaerts, future others) or sub-investigator
sharing?	(Margaretha Visser) will manage data preservation and sharing, together with the team of research
	assistants (Head Hilde Morobe). Ultimately, managing data preservation and sharing is the responsibility
	of the supervisor (Pieter Gillard).
Who will update and implement this DMP?	The PhD researchers (Jolien De Meulemeester, Laura Valgaerts, future others) or sub-investigator
	(Margaretha Visser) will update and implement this DMP, together with the team of research assistants
	(Head Hilde Morobe). Ultimately, updating and implementing this DMP is the responsibility of the
	supervisor (Pieter Gillard).